Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer: a cost-effectiveness analysis

By afschroeder • October 8, 2026

Padula WV, Cohen BG, Steel P, Appukkuttan S, Kalayeh B, Rettig M. Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer: a cost-effectiveness analysis. J Med Econ. 2026 Dec;29(1):2423-2436. doi: 10.1080/13696998.2026.2733865. Epub 2026 Oct 7. PMID: 42839780.

Tags: Androgen deprivation therapy, Androgen-receptor pathway inhibitors, Cost effectiveness, Hematology/Oncology, I00, I10, metastatic castration-sensitive prostate cancer, Publications, value-based decision making, Veterans Administration

tRNA dosage regulates lineage dependency and resistance in prostate cancer

Kim YS, Arora S, Young D, Tsou A, Shiuan A, Wladyka CL, Rudoy D, Kim JY, Waters JA, Schuster SL, Coleman IM, Kapur M, Sobczyk[...]

Rethinking the possibilities of adult ring sideroblastic anaemia

Carlson SG, Koo M, Dommaraju S, Song AH, Chai-Ho W. Rethinking the possibilities of adult ring sideroblastic anaemia. Lancet Haematol. 2026 Oct 6:S2352-3026(26)00133-X. doi: 10.1016/S2352-3026(26)00133-X.[...]

Topoisomerase-Based CDH17 Antibody Drug Conjugates Overcome P-gp Resistance but Undergo Target Mediated Clearance in Colorectal Cancer

O'Brien NA, Zhang J, Gong KW, McDermott MSJ, Hoffstrom B, Lu M, Liang M, Jia WP, Luo T, Madrid AM, Ayala R, Presta L, Larson[...]